ArticleCHEST pulmonary2024
Managing Silicosis in the United States: How I Do It.
Article in CHEST pulmonary, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Once considered a disease of the past in developed countries, silicosis is making a worrying comeback as an irreversible and potentially fatal pulmonary disease in the United States. Silicosis has been an unfortunate mainstay of respiratory disease in the developing world, but modern industries, such as stone countertop fabrication, are causing a public health crisis in the United States. This recent uptick in silicosis cases, led by the first recent case in the United States in a stone countertop worker in 2015, may be just the beginning. Because patients seem to present at a younger age with more severe disease than prior cohorts with silicosis, we have found an absence of clear guidelines and standards of care for patients with severe silicosis, particularly for those with end-stage disease. Drawing on experiences from patients with silicosis at the Los Angeles General Medical Center/University of Southern California, we have compiled a clinical review of the topic and provide our institutional approach to screening, examination, diagnosis, management, and, if necessary, referral for lung transplantation. In this "How I Do It," we share our experience from California to equip clinicians with tools to better diagnose silicosis, recognize end-stage disease, and support patients to lower the morbidity and mortality of this entirely preventable pneumoconiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.